GlassScriptPhysician profile
Ilya Kleyn
NPI 1851327092
$4,211.82
in general payments reported to CMS, 2019-2025
36 companies · $885 in 2025
The $885 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $253 · 2021: $504 · 2022: $294 · 2023: $554 · 2024: $1,170 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519 · Education: $90.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.03 |
| Education | $90.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,122.49 | 2019-2025 | |
| Horizon Therapeutics Plc | $417.75 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.00 | 2019-2024 | Xifaxan, Trulance |
| Viiv Healthcare Company | $301.44 | 2024-2025 | Apretude |
| Lilly USA, LLC | $266.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Opko Pharmaceuticals, LLC | $231.25 | 2021-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $185.26 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $150.96 | 2024-2025 | Tepezza |
| Almatica Pharma LLC | $113.58 | 2023-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Genentech USA, INC. | $106.21 | 2019-2021 | |
| Lundbeck LLC | $102.96 | 2024-2025 | Rexulti |
| Bausch Health US, LLC | $98.74 | 2020-2022 | |
| Gilead Sciences, INC. | $93.50 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $83.23 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.74 | 2025 | Caplyta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $41.05 | 2024-2025 | |
| Biogen, INC. | $34.30 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $33.82 | 2021 | |
| Ardelyx, INC. | $32.62 | 2024 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $32.23 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.89 | 2021 | |
| Novo Nordisk INC | $29.12 | 2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $27.25 | 2022 | |
| Amarin Pharma, INC. | $24.39 | 2021 | |
| Edwards Lifesciences Corporation | $23.76 | 2020 | |
| Merck Sharp & Dohme LLC | $21.88 | 2022 | |
| Vivus LLC | $21.81 | 2023 | Pancreaze |
| Shield Therapeutics INC | $21.65 | 2024 | |
| Esperion Therapeutics, INC. | $20.85 | 2021 | |
| Sumitomo Pharma America, INC. | $20.12 | 2025 | Gemtesa |
| Eisai INC. | $19.09 | 2024 | |
| Glaxosmithkline, LLC. | $18.63 | 2023 | Trelegy Ellipta |
| Ars Pharmaceuticals Operations, INC. | $18.28 | 2025 | Neffy |
| E.R. Squibb & Sons, L.L.C. | $18.22 | 2023 | Eliquis |
| Allergan, INC. | $16.26 | 2020 | |
| Pfizer INC. | $14.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Kleyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.